Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sarilumab monotherapy versus adalimumab monotherapy in rheumatoid arthritis
2014-002541-22Phase 3Completed
- Sponsor
- Sanofi
- Start
- Dec 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Sarilumab monotherapy with Adalimumab monotherapy (2 arms). Primary endpoint: Change from baseline in Disease Activity Score 28 using erythrocyte sedimentation rate. Started Dec 2014; status: completed.
02
Drugs
sarilumabadalimumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2014-002541-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002541-22.